CJ-42794| CAS 847728-01-2|DC Chemicals

Cas No.:	847728-01-2
Chemical Name:	CJ-42794
Synonyms:	(S)-4-(1-(5-Chloro-2-(4-fluorophenoxy)benzamido)ethyl)benzoic acid;(S)-4-(1-(5-Chloro-2-(4-fluorophenoxy)-benzamido)ethyl)benzoic acid;4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]Benzoic acid;CJ-042794;CJ-42794;CJ42794;4-((S)-1-(2-(4-FLUOROPHENOXY)-5-CHLOROBENZAMIDO)ETHYL)BENZOIC ACID;C22H17ClFNO4;4-((1S)-1-{[5-CHLORO-2-(4-FLUOROPHENOXY)BENZOYL]AMINO}ETHYL)BENZOIC ACID;GTPL5857;AMY36728;3044AC;BDBM50355882;4-[(1S)-1-[[5-Chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid (ACI);CJ 042794;CJ 42794;CHEBI:191023;4-{(1S)-1-[5-Chloro-2-(4-fluorophenoxy)benzamido]ethyl}benzoic acid;4-[(1S)-1-[[5-chloro-2-(4-luorophenoxy)benzoyl]amino]ethyl]benzoic acid;ANW-61958;CJ- 42794;CJ-142794;EX-A6417;Benzoic acid, 4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]-;HY-10797;DTXSID60468041;Q27076086;XIB72801;4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic Acid;CN7Z4P7QXS;MWBNCZHVEXULBD-ZDUSSCGKSA-N;CHEMBL591666;F85329;RQ-00015986;AKOS016004978;847728-01-2;MFCD13184815;SCHEMBL691577;4-((S)-1-(2-(4-Fluorophenoxy)-5-chlorobenzamido) ethyl)benzoic acid;(S)-4-(1-(5-chloro-2-(4-fluorophenoxy)benzamido)ethyl)benzoic acid;4-((1R)-1-((5-CHLORANYL-2-(4-FLUORANYLPHENOXY)PHENYL)CARBONYLAMINO)ETHYL)BENZOIC ACID;CS-5287;RQ-15986;MS-27159
SMILES:	O(C1C=CC(F)=CC=1)C1=CC=C(Cl)C=C1C(=O)N[C@H](C1C=CC(C(=O)O)=CC=1)C
Formula:	C₂₂H₁₇ClFNO₄
M.Wt:	413.826088666916
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A selective prostaglandin E receptor subtype 4 (EP4) antagonist with pKi of 8.5; displays >200-fold more selective for human EP4 receptor than EP1, EP2, and EP3; competitively inhibits PGE2-evoked elevations of intracellular cAMP levels in HEK293 cells overexpressing EP4 receptor with a mean pA(2) value of 8.6; reverses the inhibitory effects of PGE2 on LPS-induced TNFα production.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.